Ampio Pharmaceuticals Inc (OTCPK:AMPE)
$ 0.0026 -0.0725 (-96.54%) Market Cap: 3,000.00 Enterprise Value: -3.81 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Ampio Pharmaceuticals Inc to Discuss FDA Response Letter AP-013 Study - Investor Update Call Transcript

Apr 28, 2022 / 12:00PM GMT
Release Date Price: $63.6 (-15.23%)
Operator

Good morning, and welcome to the Ampio Pharmaceuticals, Inc. Investor Update Call - FDA Response Letter AP-013 Study. (Operator Instructions)

At this time, I would like to turn the call over to Dan Stokely, Chief Financial Officer. You may begin your conference.

Dan Stokely
Ampio Pharmaceuticals Inc. - CFO

Thank you, operator. This is Dan Stokely, Ampio's Chief Financial Officer, and welcome to Ampio Pharmaceuticals, April 28 conference call to provide a further update with respect to the Food and Drug Administration's response to our AP-013 study. Our Chief Executive Officer, Mike Martino, will be speaking today.

Some of our comments today contain forward-looking statements, which reflect Ampio's views about some future events. Forward-looking statements made but are not always identified by words such as believe, estimate, will, may, could, can, and other similar expressions. These matters involve risks and uncertainties that could cause Ampio's actual results to materially differ from the content of those forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot